OXU-005 is a potential first-in-class, long-lasting treatment for diabetic retinopathy.

OXU-005 contains a proprietary narrow spectrum kinase inhibitor with potent anti-angiogenic and anti-inflammatory properties. OXU-005 will be prepared using long-lasting Oxuspheres and is designed to be delivered via Oxulumis to the posterior suprachoroidal space. Preclinical studies with OXU-005 demonstrate encouraging efficacy compared to benchmark clinical molecules, with favorable toxicology data supporting human use.

Diabetic retinopathy is a serious, highly prevalent retinal disorder associated with an increased risk of vision-threatening events like retinal neovascularization, bleeding, or retinal edema.

Diabetic retinopathy affects approximately ninety-five million people globally, requiring, in more advanced stages, retinal laser therapy or frequent intravitreal injections and physician visits to prevent permanent vision loss or blindness. OXU-005’s benefits significantly address diabetic retinopathy patients’ unmet needs for (i) long treatment durability and significantly fewer injections; (ii) better efficacy and risk reduction through sustained treatment effects; (iii) and tissue-specific delivery through minimally invasive microcatheterization to the suprachoroidal space.